Banque Cantonale Vaudoise Sells 1,135 Shares of Stryker Co. (NYSE:SYK)

Banque Cantonale Vaudoise cut its stake in shares of Stryker Co. (NYSE:SYK) by 7.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,186 shares of the medical technology company’s stock after selling 1,135 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Stryker were worth $5,486,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of SYK. Centennial Bank AR boosted its position in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the last quarter. Hara Capital LLC purchased a new stake in shares of Stryker during the third quarter valued at $42,000. HBW Advisory Services LLC purchased a new stake in shares of Stryker during the third quarter valued at $42,000. Grove Bank & Trust boosted its position in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after buying an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC boosted its position in shares of Stryker by 114.3% during the third quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock valued at $49,000 after buying an additional 72 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.2 %

Shares of SYK opened at $389.40 on Tuesday. The business’s 50 day moving average is $364.61 and its 200 day moving average is $347.98. The company has a market capitalization of $148.45 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91. Stryker Co. has a 12-month low of $285.79 and a 12-month high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.46 EPS. Research analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of Stryker stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 6.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. The trade was a 17.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 67,381 shares of company stock valued at $24,825,275. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Wolfe Research started coverage on Stryker in a research report on Tuesday, September 10th. They set an “outperform” rating and a $405.00 price objective on the stock. Stifel Nicolaus dropped their target price on Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Needham & Company LLC raised their target price on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, UBS Group raised their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.